NO970317D0 - Anvendelse av DHA i en farmasöytisk blanding - Google Patents

Anvendelse av DHA i en farmasöytisk blanding

Info

Publication number
NO970317D0
NO970317D0 NO970317A NO970317A NO970317D0 NO 970317 D0 NO970317 D0 NO 970317D0 NO 970317 A NO970317 A NO 970317A NO 970317 A NO970317 A NO 970317A NO 970317 D0 NO970317 D0 NO 970317D0
Authority
NO
Norway
Prior art keywords
pct
dha
pharmaceutical composition
sec
fatty acids
Prior art date
Application number
NO970317A
Other languages
English (en)
Other versions
NO970317L (no
Inventor
Barbara Jacqueline Stordy
Original Assignee
Scotia Holdings Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scotia Holdings Plc filed Critical Scotia Holdings Plc
Publication of NO970317L publication Critical patent/NO970317L/no
Publication of NO970317D0 publication Critical patent/NO970317D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Fats And Perfumes (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
NO970317A 1995-05-25 1997-01-24 Anvendelse av DHA i en farmasöytisk blanding NO970317D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9510636.5A GB9510636D0 (en) 1995-05-25 1995-05-25 Fatty acid treatment
PCT/GB1996/001265 WO1996037200A1 (en) 1995-05-25 1996-05-24 Use of dha as a pharmaceutical composition

Publications (2)

Publication Number Publication Date
NO970317L NO970317L (no) 1997-01-24
NO970317D0 true NO970317D0 (no) 1997-01-24

Family

ID=10775045

Family Applications (1)

Application Number Title Priority Date Filing Date
NO970317A NO970317D0 (no) 1995-05-25 1997-01-24 Anvendelse av DHA i en farmasöytisk blanding

Country Status (16)

Country Link
US (1) US6150411A (no)
EP (1) EP0774962B1 (no)
JP (1) JPH10503531A (no)
KR (1) KR970704433A (no)
AT (1) ATE264676T1 (no)
AU (1) AU722474B2 (no)
CA (1) CA2195979A1 (no)
DE (1) DE69632236T2 (no)
DK (1) DK0774962T3 (no)
ES (1) ES2217317T3 (no)
FI (1) FI970298A0 (no)
GB (1) GB9510636D0 (no)
NO (1) NO970317D0 (no)
PT (1) PT774962E (no)
WO (1) WO1996037200A1 (no)
ZA (1) ZA964215B (no)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU775421B2 (en) * 1998-10-15 2004-07-29 Dsm Ip Assets B.V. Pufa supplements
KR100341109B1 (ko) * 1999-03-10 2002-06-20 이인수 인식력 및 기억력 증강용 식이 조성물
US6258846B1 (en) * 1999-06-01 2001-07-10 Drugtech Corporation Nutritional supplements
US7112609B2 (en) * 1999-06-01 2006-09-26 Drugtech Corporation Nutritional supplements
GB9918023D0 (en) 1999-07-30 1999-09-29 Unilever Plc Skin care composition
US6479545B1 (en) * 1999-09-30 2002-11-12 Drugtech Corporation Formulation for menopausal women
GB9923738D0 (en) * 1999-10-07 1999-12-08 Nestle Sa Nutritional composition
US8030348B2 (en) 2001-07-27 2011-10-04 Neptune Technologies & Bioressources, Inc. Natural marine source phospholipids comprising polyunsaturated fatty acids and their applications
US8052992B2 (en) 2003-10-22 2011-11-08 Enzymotec Ltd. Glycerophospholipids containing omega-3 and omega-6 fatty acids and their use in the treatment and improvement of cognitive functions
US20050130937A1 (en) 2003-10-22 2005-06-16 Enzymotec Ltd. Lipids containing omega-3 and omega-6 fatty acids
US7935365B2 (en) 2003-10-22 2011-05-03 Enzymotec, Ltd. Glycerophospholipids for the improvement of cognitive functions
TWI365716B (en) * 2003-12-02 2012-06-11 Suntory Holdings Ltd Oil or fat and oil compositions containing phospholipids and a long-chain polyunsaturated fatty acid supply compound, and food using same
JP2007524674A (ja) * 2004-01-19 2007-08-30 マーテック・バイオサイエンシーズ・コーポレーション リーリン欠損症または機能障害およびそれに関連する方法
US8263137B2 (en) 2005-08-04 2012-09-11 Vertical Pharmaceuticals, Inc. Nutritional supplement for women
US7901710B2 (en) 2005-08-04 2011-03-08 Vertical Pharmaceuticals, Inc. Nutritional supplement for use under physiologically stressful conditions
US7998500B2 (en) 2005-08-04 2011-08-16 Vertical Pharmaceuticals, Inc. Nutritional supplement for women
US8202546B2 (en) 2005-08-04 2012-06-19 Vertical Pharmaceuticals, Inc. Nutritional supplement for use under physiologically stressful conditions
US20070166411A1 (en) * 2005-12-16 2007-07-19 Bristol-Myers Squibb Company Nutritional supplement containing long-chain polyunsaturated fatty acids
US8343753B2 (en) * 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
GB0813599D0 (en) * 2008-07-24 2008-09-03 Pharma Marine As Method
EP2493478B8 (en) 2009-10-29 2018-03-28 Acasti Pharma, Inc. Concentrated therapeutic phospholipid compositions
US9119826B2 (en) 2011-02-16 2015-09-01 Pivotal Therapeutics, Inc. Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels
US8951514B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels
US8715648B2 (en) 2011-02-16 2014-05-06 Pivotal Therapeutics Inc. Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics
US8952000B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events
US9216199B2 (en) 2013-12-05 2015-12-22 Buriva, LLC Nutritional supplement containing phospholipid-DHA derived from eggs
US9549937B2 (en) 2013-12-05 2017-01-24 Burvia, LLC. Composition containing phospholipid-DHA and folate
US9233114B2 (en) 2013-12-05 2016-01-12 Buriva, LLC Dietary supplement containing phospholipid-DHA derived from eggs
US9610302B2 (en) 2013-12-05 2017-04-04 Buriva, LLC. Composition containing phospholipid-DHA and B vitamins
ES2877810T3 (es) * 2016-06-01 2021-11-17 Nestle Sa DGLA en la profilaxis de enfermedades alérgicas
WO2023102170A1 (en) * 2021-12-02 2023-06-08 The Regents Of The University Of California Compositions and methods for inhibiting seizures

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9224809D0 (en) * 1992-11-26 1993-01-13 Scotia Holdings Plc Schizophrenia
EP0711503A3 (en) * 1994-11-14 1997-11-26 Scotia Holdings Plc Milk fortified with GLA and/or DGLA

Also Published As

Publication number Publication date
AU722474B2 (en) 2000-08-03
HK1012575A1 (en) 1999-08-06
EP0774962B1 (en) 2004-04-21
DE69632236D1 (de) 2004-05-27
PT774962E (pt) 2004-09-30
NO970317L (no) 1997-01-24
ES2217317T3 (es) 2004-11-01
JPH10503531A (ja) 1998-03-31
AU5827796A (en) 1996-12-11
WO1996037200A1 (en) 1996-11-28
FI970298L (fi) 1997-01-24
GB9510636D0 (en) 1995-07-19
CA2195979A1 (en) 1996-11-28
ZA964215B (en) 1996-12-04
US6150411A (en) 2000-11-21
DE69632236T2 (de) 2005-04-14
DK0774962T3 (da) 2004-08-09
KR970704433A (ko) 1997-09-06
EP0774962A1 (en) 1997-05-28
ATE264676T1 (de) 2004-05-15
FI970298A7 (fi) 1997-01-24
FI970298A0 (fi) 1997-01-24

Similar Documents

Publication Publication Date Title
NO970317D0 (no) Anvendelse av DHA i en farmasöytisk blanding
ES2114616T3 (es) Acidos dicarboxilicos alifaticos insaturados.
ID21473A (id) Sediaan farmasi yang mengandung asam eikosapentanoat dan asam stearidonat
ATE216230T1 (de) Essentielle fettsäuren zur vorbeugung von kardiovaskulären anfällen
BG102011A (en) 1,3-propane diol derivatives as bioactive compounds(21) 102012 (22) 31.10.97 (13) l (19) bg (41) 29.05.98 (51) 6c 07 d 209/28 a (51) 6c 07 d 339/04 b (51) 6a 61 k 31/23 b (51) 6c 07 c 69/587 b (51) 6c 07 c 69/767 b (86) pct/gb96/01052,01.05.96 (87) wo96/34855,07.11.96 (31) 9508823 (32) 01.05.95 (33) gb (31) 9517107 (32) 21.08.95 (33) gb (31) 9605440 (32) 15.03.96 (33) gb (71) gb scotia holdings plc (72) gb horrobin, david f. (72) gb manku, mehar (72) gb mcmordie, austin (72) gb knowles, phillip (72) gb redden, peter (72) gb pitt, andrea (74) olga ruseva sirakova, (74) 1124 sofija,kompl."javorov",bl.19,vkh.g (54) fatty acid esters as bioactive compounds
ES2053990T3 (es) Composiciones de acidos grasos esenciales.
NZ299464A (en) Use of gamma linolenic or dihomogamma linolenic acid in the treatment of Huntington's Chorea
DE69409969D1 (de) Salze der mehrfach ungesättigten fettsäuren und diese enthaltende pharmazeutischen zusammensetzungen
ZA967626B (en) Lipid extract having anti-inflammatory activity.
NO940277L (no) Triglycerider og blandinger av slike
RU93047799A (ru) Композиции, содержащие ретиноевые кислоты и токоферол
KR910007858A (ko) 초기-촉진 및 향상된 진통제로서의 s(+)-이부프로펜-l-아미노산 및 s(+)-이부프로펜-d-아미노산
PT920323E (pt) Nova utilizacao de fosfolipidos de origem animal em terapeutica e/ou dietetica
NZ217703A (en) 2-(2-fluoro-4-biphenylyl) propionic acid compositions
ATE192647T1 (de) Medikamente auf der basis von docosahexaensäure, als plättchenaggregationshemmer und gegen cerebralen mangel an fettsäuren, und verfahren zur herstellung.
ATE120954T1 (de) Verwendung von essentiellen fettsäuren zur herstellung eines arzneimittels zur behandlung von aids.
AU3544693A (en) Pharmaceuticals comprising polyhydroxymethylene derivatives, process for their preparation and use
AU1821888A (en) Treatment or prevention of memory loss using essential fatty acid compositions
NZ306510A (en) Niacin derivatives which include a fatty acid or fatty acid alcohol residue and their use in medicaments and skin care compositions
ATE175344T1 (de) Gelbildende präparate, die optisch angereicherte gelbildner enthalten
ATE86108T1 (de) Omega-3-fettsaeuren zur behandlung von traumatischen verwundungen.
DE3484606D1 (en) Deodorant.
ATE161053T1 (de) Auftrennung von arylalkansäuren
DE59202373D1 (en) N-acyl-phosphatidylethanolamin als oxidationsschutzmittel.
SE9000021D0 (sv) Purified n-3 polyunsaturated fatty acids and derivatives thereof. methods of preparation and use off

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application